Role of Complement in Liver Diseases

Abstract

This review aims to summarize recent research using animal models, cell models, and human data regarding the role of complement in liver disease. Complement is part of the innate immune system and was initially characterized for its role in control of pathogens. However, evidence now indicates that complement also plays an important role in the response to cellular injury that is independent of pathogens. The liver is the main organ responsible for producing circulating complement. In response to liver injury, complement is activated and likely plays a dual role, both contributing to and protecting from injury. In uncontrolled complement activation, cell injury and liver inflammation occur, contributing to progression of liver disease. Complement activation is implicated in the pathogenesis of multiple liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, fibrosis and cirrhosis, hepatocellular carcinoma, and autoimmune hepatitis. However, the mechanisms by which complement is overactivated in liver diseases are still being unraveled.

Keywords

alcohol-associated liver disease - metabolic-associated steatotic liver disease - liver fibrosis - cirrhosis

Publikationsverlauf

Artikel online veröffentlicht:
28. November 2024

• References

• 1 Singh P, Kemper C. Complement, complosome, and complotype: a perspective. Eur J Immunol 2023; 53 (12) e2250042
• 2 West EE, Kemper C. Complosome - the intracellular complement system. Nat Rev Nephrol 2023; 19 (07) 426-439
• 3 Xiao F, Guo J, Tomlinson S, Yuan G, He S. The role of the complosome in health and disease. Front Immunol 2023; 14: 1146167
• 4 Kemper C, Ferreira VP, Paz JT, Holers VM, Lionakis MS, Alexander JJ. Complement: the road less traveled. J Immunol 2023; 210 (02) 119-125
• 5 Lo MW, Woodruff TM. Complement: bridging the innate and adaptive immune systems in sterile inflammation. J Leukoc Biol 2020; 108 (01) 339-351
• 6 Bavia L, Cogliati B, Dettoni JB, Ferreira Alves VA, Isaac L. The complement component C5 promotes liver steatosis and inflammation in murine non-alcoholic liver disease model. Immunol Lett 2016; 177: 53-61
• 7 Biewenga M, Farina Sarasqueta A, Tushuizen ME, de Jonge-Muller ESM, van Hoek B, Trouw LA. The role of complement activation in autoimmune liver disease. Autoimmun Rev 2020; 19 (06) 102534
• 8 Chen R, Du J, Zhu H, Ling Q. The role of cGAS-STING signalling in liver diseases. JHEP Rep Innov Hepatol 2021; 3 (05) 100324
• 9 Cohen JI, Roychowdhury S, McMullen MR, Stavitsky AB, Nagy LE. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 2010; 139 (02) 664-674 , 674.e1
• 10 Pritchard MT, McMullen MR, Stavitsky AB. et al. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 2007; 132 (03) 1117-1126
• 11 Roychowdhury S, McMullen MR, Pritchard MT. et al. An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice. Hepatology 2009; 49 (04) 1326-1334
• 12 Rensen SS, Slaats Y, Driessen A. et al. Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology 2009; 50 (06) 1809-1817
• 13 Xu C, Chen Y, Xu L, Miao M, Li Y, Yu C. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population. Sci Rep 2016; 6: 23279
• 14 Zhao J, Wu Y, Lu P. et al. Association of complement components with the risk and severity of NAFLD: a systematic review and meta-analysis. Front Immunol 2022; 13: 1054159
• 15 González IA, Hartley CP, Nalbantoglu I. Recurrent autoimmune hepatitis and de novo autoimmune hepatitis in the liver allograft. Am J Clin Pathol 2021; 155 (03) 435-445
• 16 Hayashi M, Abe K, Fujita M, Takahashi A, Sekine H, Ohira H. Circulating complement factor H levels are associated with disease severity and relapse in autoimmune hepatitis. JHEP Rep Innov Hepatol 2022; 4 (07) 100497
• 17 Chen B, Zhou W, Tang C. et al. Down-regulation of C3aR/C5aR inhibits cell proliferation and EMT in hepatocellular carcinoma. Technol Cancer Res Treat 2020; 19: 1533033820970668
• 18 Laskowski J, Renner B, Pickering MC. et al. Complement factor H-deficient mice develop spontaneous hepatic tumors. J Clin Invest 2020; 130 (08) 4039-4054
• 19 Li Y, Zhu S, Xue M. et al. Aristolochic acid I promotes the invasion and migration of hepatocellular carcinoma cells by activating the C3a/C3aR complement system. Toxicol Lett 2023; 378: 51-60
• 20 Pillemer L. Recent advances in the chemistry of complement. Chem Rev 1943; 33 (01) 1-26
• 21 Sim RB, Schwaeble W, Fujita T. Complement research in the 18th-21st centuries: progress comes with new technology. Immunobiology 2016; 221 (10) 1037-1045
• 22 Duval A, Frémeaux-Bacchi V. Complement biology for hematologists. Am J Hematol 2023; 98 (Suppl. 04) S5-S19
• 23 Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9 (10) 729-740
• 24 Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol 2013; 33 (06) 479-492
• 25 Killick J, Morisse G, Sieger D, Astier AL. Complement as a regulator of adaptive immunity. Semin Immunopathol 2018; 40 (01) 37-48
• 26 Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol 2017; 188 (02) 183-194
• 27 Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol 2015; 10 (09) 1636-1650
• 28 Garred P, Genster N, Pilely K. et al. A journey through the lectin pathway of complement-MBL and beyond. Immunol Rev 2016; 274 (01) 74-97
• 29 Laursen TL, Sandahl TD, Støy S. et al; US Acute Liver Failure Study Group. Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure. Liver Int 2015; 35 (03) 756-763
• 30 Reid KBM. Complement component C1q: historical perspective of a functionally versatile, and structurally unusual, serum protein. Front Immunol 2018; 9: 764
• 31 Santiesteban-Lores LE, Carneiro MC, Isaac L, Bavia L. Complement system in alcohol-associated liver disease. Immunol Lett 2021; 236: 37-50
• 32 Bayarri-Olmos R, Kirketerp-Moller N, Pérez-Alós L, Skjodt K, Skjoedt MO, Garred P. Development of a quantitative assay for the characterization of human collectin-11 (CL-11, CL-K1). Front Immunol 2018; 9: 2238
• 33 Arbore G, West EE, Spolski R. et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells. Science 2016; 352 (6292) aad1210
• 34 Fan X, McCullough RL, Huang E. et al. Diagnostic and prognostic significance of complement in patients with alcohol-associated hepatitis. Hepatology 2021; 73 (03) 983-997
• 35 Fishelson Z, Kirschfink M. Complement C5b-9 and cancer: mechanisms of cell damage, cancer counteractions, and approaches for intervention. Front Immunol 2019; 10: 752
• 36 Garlatti V, Martin L, Lacroix M. et al. Structural insights into the recognition properties of human ficolins. J Innate Immun 2010; 2 (01) 17-23
• 37 Hallam TM, Sharp SJ, Andreadi A, Kavanagh D. Complement factor I: regulatory nexus, driver of immunopathology, and therapeutic. Immunobiology 2023; 228 (05) 152410
• 38 Liszewski MK, Atkinson JP. Alternative pathway activation: ever ancient and ever new. Immunol Rev 2023; 313 (01) 60-63
• 39 Thurman JM, Fremeaux-Bacchi V. Alternative pathway diagnostics. Immunol Rev 2023; 313 (01) 225-238
• 40 Schubart A, Flohr S, Junt T, Eder J. Low-molecular weight inhibitors of the alternative complement pathway. Immunol Rev 2023; 313 (01) 339-357
• 41 Wang Y, Liu W, Xu Y. et al. Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins. Nat Chem Biol 2023; 19 (11) 1351-1360
• 42 Niyonzima N, Rahman J, Kunz N. et al. Mitochondrial C5aR1 activity in macrophages controls IL-1β production underlying sterile inflammation. Sci Immunol 2021; 6 (66) eabf2489
• 43 McCullough RL, McMullen MR, Das D. et al. Differential contribution of complement receptor C5aR in myeloid and non-myeloid cells in chronic ethanol-induced liver injury in mice. Mol Immunol 2016; 75: 122-132
• 44 McCullough RL, McMullen MR, Poulsen KL, Kim A, Medof ME, Nagy LE. Anaphylatoxin receptors C3aR and C5aR1 are important factors that influence the impact of ethanol on the adipose secretome. Front Immunol 2018; 9: 2133
• 45 Serna M, Giles JL, Morgan BP, Bubeck D. Structural basis of complement membrane attack complex formation. Nat Commun 2016; 7: 10587
• 46 Doorduijn DJ, Rooijakkers SHM, Heesterbeek DAC. How the membrane attack complex damages the bacterial cell envelope and kills gram-negative bacteria. BioEssays 2019; 41 (10) e1900074
• 47 McCullough RL, McMullen MR, Sheehan MM. et al. Complement factor D protects mice from ethanol-induced inflammation and liver injury. Am J Physiol Gastrointest Liver Physiol 2018; 315 (01) G66-G79
• 48 Cresci GA, Allende D, McMullen MR, Nagy LE. Alternative complement pathway component Factor D contributes to efficient clearance of tissue debris following acute CCl₄-induced injury. Mol Immunol 2015; 64 (01) 9-17
• 49 Jensen RK, Bajic G, Sen M, Springer TA, Vorup-Jensen T, Andersen GR. Complement receptor 3 forms a compact high-affinity complex with iC3b. J Immunol 2021; 206 (12) 3032-3042
• 50 Gankema AAF, Furumaya C, Fernández-Hermira S. et al. Efficient complement-mediated clearance of immunosuppressed T cells by macrophages. Front Immunol 2023; 14: 1183180
• 51 Helmy KY, Katschke Jr KJ, Gorgani NN. et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006; 124 (05) 915-927
• 52 Fraser DA, Tenner AJ. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol 2010; 185 (07) 3932-3939
• 53 Biró A, Thielens NM, Cervenák L, Prohászka Z, Füst G, Arlaud GJ. Modified low density lipoproteins differentially bind and activate the C1 complex of complement. Mol Immunol 2007; 44 (06) 1169-1177
• 54 Pulanco MC, Cosman J, Ho MM. et al. Complement protein C1q enhances macrophage foam cell survival and efferocytosis. J Immunol 2017; 198 (01) 472-480
• 55 Brubaker WD, Crane A, Johansson JU. et al. Peripheral complement interactions with amyloid β peptide: erythrocyte clearance mechanisms. Alzheimers Dement 2017; 13 (12) 1397-1409
• 56 Trouw LA, Nilsson SC, Gonçalves I, Landberg G, Blom AM. C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 2005; 201 (12) 1937-1948
• 57 Werner LM, Criss AK. Diverse functions of C4b-binding protein in health and disease. J Immunol 2023; 211 (10) 1443-1449
• 58 Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM. Complement factor I in health and disease. Mol Immunol 2011; 48 (14) 1611-1620
• 59 Gerogianni A, Baas LM, Sjöström DJ. et al. Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE. Front Immunol 2023; 14: 1279612
• 60 Kremlitzka M, Nowacka AA, Mohlin FC, Bompada P, De Marinis Y, Blom AM. Interaction of serum-derived and internalized C3 with DNA in human B Cells-A potential involvement in regulation of gene transcription. Front Immunol 2019; 10: 493
• 61 King BC, Renström E, Blom AM. Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1. Autophagy 2019; 15 (05) 919-921
• 62 Kolev M, Dimeloe S, Le Friec G. et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 2015; 42 (06) 1033-1047
• 63 Liszewski MK, Kolev M, Le Friec G. et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 2013; 39 (06) 1143-1157
• 64 Asgari E, Le Friec G, Yamamoto H. et al. C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013; 122 (20) 3473-3481
• 65 Reichhardt MP, Meri S. Intracellular complement activation-an alarm raising mechanism?. Semin Immunol 2018; 38: 54-62
• 66 Smathers RL, Chiang DJ, McMullen MR, Feldstein AE, Roychowdhury S, Nagy LE. Soluble IgM links apoptosis to complement activation in early alcoholic liver disease in mice. Mol Immunol 2016; 72: 9-18
• 67 Shen H, French BA, Liu H, Tillman BC, French SW. Increased activity of the complement system in the liver of patients with alcoholic hepatitis. Exp Mol Pathol 2014; 97 (03) 338-344
• 68 Duan Y, Chu H, Brandl K. et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat Commun 2021; 12 (01) 7172
• 69 Taiwo M, Huang E, Pathak V. et al; Alcohol Hepatitis Network (AlcHepNet) Consortium. Proteomics identifies complement protein signatures in patients with alcohol-associated hepatitis. JCI Insight 2024; 9 (09) e174127
• 70 Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr 2023; 32 (03) 197-213
• 71 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023; 78 (06) 1966-1986
• 72 Moreno-Navarrete JM, Fernández-Real JM. The complement system is dysfunctional in metabolic disease: evidences in plasma and adipose tissue from obese and insulin resistant subjects. Semin Cell Dev Biol 2019; 85: 164-172
• 73 Wu X, Hutson I, Akk AM. et al. Contribution of adipose-derived factor D/adipsin to complement alternative pathway activation: lessons from lipodystrophy. J Immunol 2018; 200 (08) 2786-2797
• 74 Gupta A, Rezvani R, Lapointe M. et al. Downregulation of complement C3 and C3aR expression in subcutaneous adipose tissue in obese women. PLoS One 2014; 9 (04) e95478
• 75 Li Y, Sha Y, Wang H. et al. Intracellular C3 prevents hepatic steatosis by promoting autophagy and very-low-density lipoprotein secretion. FASEB J 2021; 35 (12) e22037
• 76 Harris CL, Heurich M, Rodriguez de Cordoba S, Morgan BP. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012; 33 (10) 513-521
• 77 Heurich M, Martínez-Barricarte R, Francis NJ. et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011; 108 (21) 8761-8766
• 78 Vasel M, Rutz R, Bersch C. et al. Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. Clin Immunol 2014; 150 (02) 149-156
• 79 Zhang X, Wan Z, Lin M. et al. Immunoglobulin A and complement C4 are involved in the progression of liver fibrosis in patients with chronic hepatitis B. Int Immunopharmacol 2023; 122: 110604
• 80 Lian M, Wang Q, Chen S, Yang Y, Hong G. The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B. J Viral Hepat 2023; 30 (05) 437-447
• 81 Deng Y, Zhao H, Zhou J, Yan L, Wang G. China HepB-Related Fibrosis Assessment Research Group. Complement 5a is an indicator of significant fibrosis and earlier cirrhosis in patients chronically infected with hepatitis B virus. Infection 2017; 45 (01) 75-81
• 82 Zhang S, Cao X, Liu C. et al. N-glycopeptide signatures of IgA₂ in serum from patients with hepatitis B virus-related liver diseases. Mol Cell Proteomics 2019; 18 (11) 2262-2272
• 83 Das D, Barnes MA, Nagy LE. Anaphylatoxin C5a modulates hepatic stellate cell migration. Fibrogenesis Tissue Repair 2014; 7: 9
• 84 Bezerra JA, Currier AR, Melin-Aldana H. et al. Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 2001; 158 (03) 921-929
• 85 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
• 86 Mao X, Zhou L, Tey SK. et al. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. J Extracell Vesicles 2020; 10 (01) e12031
• 87 Qian X, Yang Z, Gao L, Liu Y, Yan J. The role of complement in the clinical course of hepatocellular carcinoma. Immun Inflamm Dis 2022; 10 (03) e569
• 88 Corrales L, Ajona D, Rafail S. et al. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012; 189 (09) 4674-4683
• 89 Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the cancer-immunity cycle. Front Immunol 2019; 10: 774
• 90 Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018; 18 (01) 5-18
• 91 Zent CS, Secreto CR, LaPlant BR. et al. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008; 32 (12) 1849-1856
• 92 Feng G, Li J, Zheng M. et al. Hepatitis B virus X protein up-regulates C4b-binding protein α through activating transcription factor Sp1 in protection of hepatoma cells from complement attack. Oncotarget 2016; 7 (19) 28013-28026
• 93 Yuan Y, Xu J, Jiang Q. et al. Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis. J Exp Clin Cancer Res 2024; 43 (01) 133
• 94 Kusakabe J, Hata K, Miyauchi H. et al. Complement-5 inhibition deters progression of fulminant hepatitis to acute liver failure in murine models. Cell Mol Gastroenterol Hepatol 2021; 11 (05) 1351-1367
• 95 Muratori L, Lohse AW, Lenzi M. Diagnosis and management of autoimmune hepatitis. BMJ 2023; 380: e070201
• 96 Aguilera I, Sousa JM, Gavilan F, Gomez L, Alvarez-Márquez A, Núñez-Roldán A. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17 (07) 779-788
• 97 European Association for the Study of the Liver. Electronic address: [e-mail], Clinical Practice Guideline Panel, Chair, EASL Governing Board representative, Panel members. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021; 75 (03) 659-689
• 98 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2021; 18 (04) 223-238
• 99 Korkiakoski A, Käräjämäki AJ, Ronkainen J. et al. Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study. Scand J Clin Lab Invest 2022; 82 (03) 173-180
• 100 Ngu NLY, Flanagan E, Bell S, Le ST. Acute-on-chronic liver failure: controversies and consensus. World J Gastroenterol 2023; 29 (02) 232-240
• 101 Sanyal AJ, Van Natta ML, Clark J. et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385 (17) 1559-1569
• 102 Taylor RS, Taylor RJ, Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
• 103 Thakral N, Deutsch-Link S, Singal AK. Therapeutic pipeline in alcohol-associated liver disease. Semin Liver Dis 2023; 43 (01) 60-76
• 104 Eguchi A, Iwasa M, Sugimoto R. et al. Complement complex 1 subunit q-mediated hepatic stellate cell activation with connective tissue growth factor elevation is a prognostic factor for survival in rat and human chronic liver diseases. Hepatol Commun 2022; 6 (12) 3515-3527
• 105 Chen C, Yuan Z, Li W. et al. Complement C3 facilitates stratification of stages of chronic hepatitis B and signifies development of acute-on-chronic liver failure in acute decompensated cirrhosis. Adv Ther 2023; 40 (03) 1171-1186
• 106 Thorgersen EB, Barratt-Due A, Haugaa H. et al. The role of complement in liver injury, regeneration, and transplantation. Hepatology 2019; 70 (02) 725-736
• 107 West EE, Woodruff T, Fremeaux-Bacchi V, Kemper C. Complement in human disease: approved and up-and-coming therapeutics. Lancet 2024; 403 (10424): 392-405
• 108 Versino F, Fattizzo B. Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. Int J Lab Hematol 2024; 46 (Suppl. 01) 43-54
• 109 Kelly RJ, Holt M, Vidler J. et al. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. Blood 2024; 143 (12) 1157-1166
• 110 de Latour RP, Szer J, Weitz IC. et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol 2022; 9 (09) e648-e659
• 111 Peffault de Latour R, Röth A, Kulasekararaj AG. et al. Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2024; 390 (11) 994-1008
• 112 Bjanes E, Nizet V. More than a pore: nonlytic antimicrobial functions of complement and bacterial strategies for evasion. Microbiol Mol Biol Rev 2021; 85 (01) e00177-20
• 113 Bharti R, Dey G, Lin F, Lathia J, Reizes O. CD55 in cancer: complementing functions in a non-canonical manner. Cancer Lett 2022; 551: 215935
• 114 Lucientes-Continente L, Márquez-Tirado B, Goicoechea de Jorge E. The factor H protein family: the switchers of the complement alternative pathway. Immunol Rev 2023; 313 (01) 25-45
• 115 Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol 2009; 183 (11) 7371-7378
• 116 Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ 2014; 349: g4596
• 117 Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340: c1240